Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC42H41F3N12O8 |
InChIKeyAFCBPOSVCVAUDT-UHFFFAOYSA-N |
CAS Registry2360530-72-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 29 Dec 2020 |